Close
CDMO Safety Testing 2026
Novotech

New calcium ingredient with improved flow and compactability properties

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Quantum machine learning in pharma research growth

The convergence of artificial intelligence and quantum processing is opening new avenues for rapid discovery and innovation within the life sciences. By utilizing advanced mathematical models that operate across multi-dimensional datasets, researchers can now identify complex biological patterns and predict molecular behaviors with a speed that surpasses traditional computational methods. This transformation is accelerating the development of novel therapies and providing deeper insights into disease mechanisms, fundamentally altering the trajectory of pharmaceutical research and development.

Quantum sensors enabling advanced drug diagnostics

The landscape of medical diagnostics is being reshaped by the introduction of sensing technologies that operate with atomic-level sensitivity. By providing high-fidelity measurements and real-time data, these tools allow for the detection of subtle biological changes and chemical markers that were previously invisible to conventional equipment. This advancement is enhancing the precision of drug testing and clinical monitoring, leading to earlier disease detection and more effective therapeutic interventions across the global healthcare spectrum.

Quantum computing optimizing pharma supply chains

The global distribution of pharmaceutical products is facing unprecedented challenges that demand a new level of logistical precision and resilience. By utilizing advanced analytical models, companies can now navigate complex international networks with greater efficiency, ensuring that temperature-sensitive medicines and life-saving therapies reach their destinations without delay. This evolution toward a more intelligent and responsive supply chain is critical for maintaining public health and responding effectively to emerging medical needs on a global scale.
- Advertisement -

At this year’s CPhI Worldwide, mineral producer Omya will launch its new Calcipur® DC range, which comprises seven different grades of high-purity, directly compressible and free-flowing Natural Calcium Carbonates. Thanks to improved processing properties, the ingredient is ideally suited for the production of calcium-containing dietary supplements, such as tablets, capsules and stick packs. Calcipur® DC can be used as an active ingredient in nutraceuticals and as a diluent in pharmaceuticals.  

By turning calcium carbonate into a granulate, Omya has developed an ingredient range that offers improved flow and compactability properties. Calcipur® DC consists of high-purity calcium carbonate granulated with 5-10 % w/w of binder. The binders used in Calcipur® DC are gluten-free maltodextrin, non-GMO corn starch or a mixture of acacia gum and gluten-free maltodextrin. All starting materials for Calcipur® DC products are food (FCC compliant) and pharma grade (EP/USP).

The Calcipur® DC range is an excellent source of elemental calcium, providing a similar level of calcium bioavailability to other calcium salts. All grades have a bioavailable calcium content of at least 36%, coming from the active ingredient, calcium carbonate. Upon ingestion, the calcium carbonate is solubilized into calcium ions in the acidic environment of the stomach and then absorbed through the intestine.

In the EU, the recommended daily intake of calcium, irrespective of gender or age, is set at 800 mg/day. To be claimed as a “source of calcium”, a product has to contain more than 120 mg (15% of the RDA) per dose, which translates into 316-333 mg of Calcipur® DC, depending on the grade used. In order to claim to be a “high in calcium” food supplement, the end product must contain at least 240 mg of calcium, which corresponds to 632-667 mg of Calcipur® DC.

In addition to the new range, the company will also present samples containing its functional mineral excipient Omyapharm®. This highly porous inactive ingredient facilitates the production of tablets and granules with excellent compactability, good mechanical stability, high absorption capacity and rapid disintegration.

Stefan Lander, Vice President Consumer Goods, Group Sales & Marketing at Omya, comments: “As a leading producer of minerals, we put a strong focus on R&D. This includes developing innovative minerals that are tailor-made for specific requirements. With our seven new Calcipur® DC grades, we are supporting our customers by optimizing their products and providing multiple benefits, such as improved flow and compactability properties.”

About Omya Group
Omya International AG is a leading global producer of calcium carbonates and a worldwide distributor of specialty additives, premium services and solutions. Founded in 1884 in Switzerland, Omya has a global presence extending to 175 locations in over 50 countries with 8,000 employees. Omya provides sustainable added value products and services from responsibly sourced materials to meet the needs of current and future generations. In the Consumer Goods sector, Omya offers innovative solutions based on high purity natural minerals and complementary ingredients that comply with the most stringent regulatory and quality standards.

For further information, please visit www.omya.com

Latest stories

Related stories

Quantum machine learning in pharma research growth

The convergence of artificial intelligence and quantum processing is opening new avenues for rapid discovery and innovation within the life sciences. By utilizing advanced mathematical models that operate across multi-dimensional datasets, researchers can now identify complex biological patterns and predict molecular behaviors with a speed that surpasses traditional computational methods. This transformation is accelerating the development of novel therapies and providing deeper insights into disease mechanisms, fundamentally altering the trajectory of pharmaceutical research and development.

Quantum sensors enabling advanced drug diagnostics

The landscape of medical diagnostics is being reshaped by the introduction of sensing technologies that operate with atomic-level sensitivity. By providing high-fidelity measurements and real-time data, these tools allow for the detection of subtle biological changes and chemical markers that were previously invisible to conventional equipment. This advancement is enhancing the precision of drug testing and clinical monitoring, leading to earlier disease detection and more effective therapeutic interventions across the global healthcare spectrum.

Quantum computing optimizing pharma supply chains

The global distribution of pharmaceutical products is facing unprecedented challenges that demand a new level of logistical precision and resilience. By utilizing advanced analytical models, companies can now navigate complex international networks with greater efficiency, ensuring that temperature-sensitive medicines and life-saving therapies reach their destinations without delay. This evolution toward a more intelligent and responsive supply chain is critical for maintaining public health and responding effectively to emerging medical needs on a global scale.

Quantum security strengthening pharma data protection

Protecting sensitive patient information and proprietary research data is becoming a critical priority as the pharmaceutical industry navigates an increasingly complex digital landscape. By integrating advanced cryptographic methods and secure communication protocols, researchers can ensure the integrity of their clinical findings and the privacy of those involved in medical trials. This shift toward a more resilient digital infrastructure is essential for maintaining public trust and fostering global collaboration in the pursuit of life-saving therapeutic breakthroughs.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »